These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28379024)

  • 21. Empagliflozin for the treatment of type 2 diabetes.
    Jahagirdar V; Barnett AH
    Expert Opin Pharmacother; 2014 Nov; 15(16):2429-41. PubMed ID: 25301180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absolute benefits of empagliflozin in type 2 diabetes: a game changer?
    Kumana CR; Tan KCB; Cheung BMY
    Postgrad Med J; 2017 Jul; 93(1101):373-375. PubMed ID: 28433975
    [No Abstract]   [Full Text] [Related]  

  • 24. Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus.
    Zimmermann J
    Am Fam Physician; 2016 Dec; 94(12):1014-1015. PubMed ID: 28075091
    [No Abstract]   [Full Text] [Related]  

  • 25. ▼ Empagliflozin, diabetes and outcomes.
    Drug Ther Bull; 2016 Jul; 54(7):78-81. PubMed ID: 27417322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empagliflozin (Jardiance) for diabetes.
    Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258
    [No Abstract]   [Full Text] [Related]  

  • 27. Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?
    Kaul S
    Circulation; 2016 Jul; 134(2):94-6. PubMed ID: 27400894
    [No Abstract]   [Full Text] [Related]  

  • 28. Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
    Cusi K
    Curr Opin Lipidol; 2016 Dec; 27(6):633-635. PubMed ID: 27805974
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
    Rossello X; Yellon DM
    Int J Cardiol; 2017 Feb; 228():198-200. PubMed ID: 27865185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving beta-cell secretory function and glycaemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, continuous glucose monitor-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide.
    Middleton TL; Constantino MI; McGill M; D'Souza M; Yue DK; Twigg SM; Wu T; Wong J
    Diabetes Obes Metab; 2022 Apr; 24(4):747-751. PubMed ID: 34882926
    [No Abstract]   [Full Text] [Related]  

  • 32. [New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes].
    Rušavý Z
    Vnitr Lek; 2014 Nov; 60(11):926-7, 929-30. PubMed ID: 25600037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.
    Morillas C
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():49-53. PubMed ID: 28760226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Rosenstein R; Hough A
    N Engl J Med; 2016 Mar; 374(11):1093-4. PubMed ID: 26981944
    [No Abstract]   [Full Text] [Related]  

  • 35. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Edwards JL
    N Engl J Med; 2016 Mar; 374(11):1093. PubMed ID: 26981943
    [No Abstract]   [Full Text] [Related]  

  • 36. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Fischereder M; Schönermarck U
    N Engl J Med; 2016 Mar; 374(11):1092-3. PubMed ID: 26981942
    [No Abstract]   [Full Text] [Related]  

  • 37. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Sarafidis PA; Tsapas A
    N Engl J Med; 2016 Mar; 374(11):1092. PubMed ID: 26981941
    [No Abstract]   [Full Text] [Related]  

  • 38. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B; Lachin JM; Inzucchi SE
    N Engl J Med; 2016 Mar; 374(11):1094. PubMed ID: 26981940
    [No Abstract]   [Full Text] [Related]  

  • 39. Low Reported Adherence to the 2019 American Diabetes Association Nutrition Recommendations among Patients with Type 2 Diabetes Mellitus, Indicating the Need for Improved Nutrition Education and Diet Care.
    Katsaridis S; Grammatikopoulou MG; Gkiouras K; Tzimos C; Papageorgiou ST; Markaki AG; Exiara T; Goulis DG; Papamitsou T
    Nutrients; 2020 Nov; 12(11):. PubMed ID: 33203138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
    Kaul S
    Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.